Alterity Therapeutics Limited
ATHEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAlterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. With a market capitalization of $82.7M, it sits in micro-cap territory. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.
Market Cap
$82.7M
Beta
-0.04
P/E (TTM)
—
P/E (Fwd)
-4.74
EPS (TTM)
$-0.96
EPS (Fwd)
$-0.96
ROE
-55.0%
ROA
-34.1%
Cash
$37.3M
Total Debt
$193,465
Free CF
-$14.7M
52W Change
-12.6%
Annual Financials
Cash vs Debt
Where ATHE stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ATHE finished 7.36% above its 150-day moving average ($4.21) and 13.00% above its 200-day moving average ($4.00). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ATHE overbought or oversold?
At the September 3, 2026 close, ATHE's RSI(14) was 45.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $37.3M in cash and $193K in debt, ATHE maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$14.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -55.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Alterity Therapeutics Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ATHE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.